Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.

Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets

Open access
Zhang, Ji-chun, Yao, Wei, Hashimoto, Kenji · 2016 · Current Neuropharmacology

Abstract

Depression is the most prevalent and among the most debilitating of psychiatric disorders. The precise neurobiology of this illness is unknown. Several lines of evidence suggest that peripheral and central inflammation plays a role in depressive symptoms, and that anti-inflammatory drugs can improve depressive symptoms in patients with inflammation-related depression. Signaling via brain-derived neurotrophic factor (BDNF) and its receptor, tropomycin receptor kinase B (TrkB) plays a key role in the pathophysiology of depression and in the therapeutic mechanisms of antidepressants. A recent paper showed that lipopolysaccharide (LPS)-induced inflammation gave rise to depression-like phenotype by altering BDNF-TrkB signaling in the prefrontal cortex, hippocampus, and nucleus accumbens, areas thought to be involved in the antidepressant effects of TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF) and TrkB antagonist, ANA-12. Here we provide an overview of the tryptophan-kynurenine pathway and BDNF-TrkB signaling in the pathophysiology of inflammation-induced depression, and propose mechanistic actions for potential therapeutic agents. Additionally, the authors discuss the putative role of TrkB agonists and antagonists as novel therapeutic drugs for inflammation-related depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x14666160119094646

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) The relationship between sickness behavior and depression-like behavior. (A): The sickness behavior that peaks 2 to 6 hours later and gradually wanes by peripheral administration of lipopolysaccharide (LPS). Pro-inflammatory cytokine signaling is activated in the brain as a response to peripheral LPS injection, with depression-like behavior peaking 24 hours after LPS injection. (B): The sickness behavior was induced by pro-inflammatory cytokines which also can enhance activity of the ubiquitous indoleamine 2,3-dioxygenase (IDO), peaking 24 hours after LPS administration. Activation of IDO results in decreased tryptophan (TRP) levels and increased production of kynurenine (KYN) and other tryptophan-derived metabolites. Anti-inflammatory drugs (e.g. minocycline) can block both LPS-induced sickness behavior and depression-like behavior. By contrast, administration of 1-methyl tryptophan (1-MT), a competitive inhibitor of IDO, blocks LPS induced depression-like behavior without altering LPS-induced sickness behavior. This figure is a modified version from a previous report [45].
Fig. (1) The relationship between sickness behavior and depression-like behavior. (A): The sickness behavior that peaks 2 to 6 hours later and gradually wanes by peripheral administration of lipopolysaccharide (LPS). Pro-inflammatory cytokine signaling is activated in the brain as a response to peripheral LPS injection, with depression-like behavior peaking 24 hours after LPS injection. (B): The sickness behavior was induced by pro-inflammatory cytokines which also can enhance activity of the ubiquitous indoleamine 2,3-dioxygenase (IDO), peaking 24 hours after LPS administration. Activation of IDO results in decreased tryptophan (TRP) levels and increased production of kynurenine (KYN) and other tryptophan-derived metabolites. Anti-inflammatory drugs (e.g. minocycline) can block both LPS-induced sickness behavior and depression-like behavior. By contrast, administration of 1-methyl tryptophan (1-MT), a competitive inhibitor of IDO, blocks LPS induced depression-like behavior without altering LPS-induced sickness behavior. This figure is a modified version from a previous report [45].CC BY-NC · PubMed Central
Fig. (2) Tryptophan-kynurenine pathway. The essential amino acid L-tryptophan is converted to 5-hydroxytryptophan by tryptophan hydroxylase (TPH), and this is metabolized to serotonin (5-HT) by 5-hydroxytryptophan decarboxylase. The kynurenine pathway is initiated by the conversion of tryptophan to kynurenine by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). Kynurenine is mostly hydroxylated (kynurenine hydroxylase) to 3-hydroxykynurenine. Kynureninase acts upon both 3-hydroxykynurenine and kynurenine; on 3-hydroxykynurenine to form 3-hydroxyanthranilic acid; and on kynurenine to form anthranilic acid (this latter conversion accounts for only a minority of kynureninase activity). Three-hydroxyanthranilic acid is converted into quinolinic acid, an NMDA receptor agonist by 3-hydroxyanthranilic acid oxygenase. Kynurenine can also be converted into kynurenic acid by kynurenine aminotransferase. By contrast, kynurenic acid is an antagonist at NMDA and α7 nicotinic acetylcholine receptors (nAChRs), both of which play roles in the pathophysiology of psychiatric disease.
Fig. (2) Tryptophan-kynurenine pathway. The essential amino acid L-tryptophan is converted to 5-hydroxytryptophan by tryptophan hydroxylase (TPH), and this is metabolized to serotonin (5-HT) by 5-hydroxytryptophan decarboxylase. The kynurenine pathway is initiated by the conversion of tryptophan to kynurenine by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). Kynurenine is mostly hydroxylated (kynurenine hydroxylase) to 3-hydroxykynurenine. Kynureninase acts upon both 3-hydroxykynurenine and kynurenine; on 3-hydroxykynurenine to form 3-hydroxyanthranilic acid; and on kynurenine to form anthranilic acid (this latter conversion accounts for only a minority of kynureninase activity). Three-hydroxyanthranilic acid is converted into quinolinic acid, an NMDA receptor agonist by 3-hydroxyanthranilic acid oxygenase. Kynurenine can also be converted into kynurenic acid by kynurenine aminotransferase. By contrast, kynurenic acid is an antagonist at NMDA and α7 nicotinic acetylcholine receptors (nAChRs), both of which play roles in the pathophysiology of psychiatric disease.CC BY-NC · PubMed Central
Fig. (3) Structure of proBDNF and mature BDNF. (A): Arrowheads indicate known protease cleavage sites involved in the processing to mature BDNF. The position of the single nucleotide polymorphism (rs6265, Val66Met) in human BDNF is indicated by arrows. (B): Extrasynaptic cleavage of proBDNF to mature BDNF. ProBDNF preferentially binds p75NTR. ProBDNF is cleaved by extracellular proteases at synapses and converted to mature BDNF. Mature BDNF preferentially binds the TrkB receptor. This figure is a modified version taken from a previous report (88).
Fig. (3) Structure of proBDNF and mature BDNF. (A): Arrowheads indicate known protease cleavage sites involved in the processing to mature BDNF. The position of the single nucleotide polymorphism (rs6265, Val66Met) in human BDNF is indicated by arrows. (B): Extrasynaptic cleavage of proBDNF to mature BDNF. ProBDNF preferentially binds p75NTR. ProBDNF is cleaved by extracellular proteases at synapses and converted to mature BDNF. Mature BDNF preferentially binds the TrkB receptor. This figure is a modified version taken from a previous report (88).CC BY-NC · PubMed Central
Fig. (4) Schematic outline for the proposed use of TrkB ligands as novel therapeutic drugs in depression. In preclinical studies, inflammation promotes reduced BDNF in the PFC and hippocampus, as well as increased BDNF in the NAc of the brain, resulting in a depression-like phenotype in rodents. From preclinical data, we propose that TrkB agonists and current antidepressants, such as SSRIs and SNRIs could be effective therapeutic drugs for depressed patients with decreased levels of BDNF in the PFC and hippocampus. In contrast, TrkB antagonists confer potential therapeutic benefits for patients with treatment-resistant depression showing increased BDNF levels in the VTA-NAc pathway.
Fig. (4) Schematic outline for the proposed use of TrkB ligands as novel therapeutic drugs in depression. In preclinical studies, inflammation promotes reduced BDNF in the PFC and hippocampus, as well as increased BDNF in the NAc of the brain, resulting in a depression-like phenotype in rodents. From preclinical data, we propose that TrkB agonists and current antidepressants, such as SSRIs and SNRIs could be effective therapeutic drugs for depressed patients with decreased levels of BDNF in the PFC and hippocampus. In contrast, TrkB antagonists confer potential therapeutic benefits for patients with treatment-resistant depression showing increased BDNF levels in the VTA-NAc pathway.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 131 references

Research works printed but not linked: 2

  1. [97]Duman R.S. Heninger G.R. Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997 54 7 597 606 [http://dx.doi.org/10.1001/archpsyc.1997.01830190015002]. [PMID: 9236543]. 9236543 · DOI · Paper page
  2. [102]Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog. Neurobiol. 2013 100 15 29 [pneurobio.].[http://dx.doi.org/10.1016/j.pneurobio.2012.09.001]. [PMID: 23044468]. 23044468 · DOI · Paper page

Cited by

See all 561

Metadata

Authors
Zhang, J.-C., Yao, W., & Hashimoto, K.
Affiliations
Chiba University (JP)
Corresponding author
Hashimoto, Kenji
Venue
Current Neuropharmacology
Published
2016-08-26
Volume
14
Issue
7
Pages
721-731
ISSN
1570-159X (ISSN-L)
OpenAlex
W2309165118
Cited by
538
References
131
Citations by year
2026: 46 · 2025: 71 · 2024: 70 · 2023: 71 · 2022: 65 · 2021: 60 · 2020: 64 · 2019: 37 · 2018: 22 · 2017: 18 · 2016: 14
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (24116006)
  • Japan Society for the Promotion of Science (15K19711)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
brain-derived neurotrophic factor, TrkB signaling, neuroinflammation, kynurenine pathway, lipopolysaccharide-induced inflammation, antidepressant mechanism, 7,8-dihydroxyflavone, ANA-12, TrkB agonist, prefrontal cortex, hippocampus, nucleus accumbens
MeSH terms
Animals, Anti-Inflammatory Agents, Antidepressive Agents, Brain, Depressive Disorder, Humans, Inflammation, Brain-Derived Neurotrophic Factor, Receptor, trkB

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. https://app.cochat.ai/papers/10.2174/1570159x14666160119094646
The paper
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016). Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. Current Neuropharmacology. https://doi.org/10.2174/1570159x14666160119094646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.